Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.72 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.72 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.64 |
| ▸ | TSHR | P16473 | 3/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.64 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | CDK9 | P50750 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3237044 | 0.87 | KDM4E (0.77) | KDM4ESMN1; SMN2HSD17B10CYP2C9ALDH1A1 | |
| SCHEMBL27182653 | 0.84 | CYP2C9 (0.68) | KDM4ESMN1; SMN2HSD17B10CYP2C9ALDH1A1 | |
| SCHEMBL30872941 | 0.84 | CYP2C9 (0.68) | KDM4ESMN1; SMN2HSD17B10CYP2C9ALDH1A1 | |
| SCHEMBL8068415 | 0.84 | KDM4E (0.72) | KDM4ESMN1; SMN2HSD17B10CYP2C9ALDH1A1 | |
| SCHEMBL29791318 | 0.83 | NEU3 (0.56) | KDM4ESMN1; SMN2HSD17B10CYP2C9ALDH1A1 | |
| SCHEMBL4176955 | 0.83 | NEU3 (0.56) | KDM4ESMN1; SMN2HSD17B10CYP2C9ALDH1A1 | |
| SCHEMBL8472161 | 0.83 | KDM4E (0.67) | KDM4ESMN1; SMN2HSD17B10CYP2C9ALDH1A1 | |
| SCHEMBL5440367 | 0.83 | KDM4E (0.70) | KDM4ESMN1; SMN2HSD17B10CYP2C9ALDH1A1 | |
| SCHEMBL15754401 | 0.83 | KDM4E (0.70) | KDM4ESMN1; SMN2HSD17B10CYP2C9ALDH1A1 | |
| SCHEMBL5071184 | 0.83 | SMN1; SMN2 (0.70) | KDM4ESMN1; SMN2HSD17B10CYP2C9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739682-A1 | 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS | Janssen Pharmaceutica NV (BE) | 2026-05-13 | — | — | EP | disclosed |
| WO-2025008058-A1 | 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS | JANSSEN PHARMACEUTICA NV (BE) | 2025-01-09 | — | — | WO | disclosed |
| US-20090105305-A1 | Therapeutic Agents - 550 | ASTRAZENECA AB (SE) | 2009-04-23 | — | — | US | disclosed |
| US-20090105305-A1 | Therapeutic Agents - 550 | ASTRAZENECA AB (SE) | 2009-04-23 | — | — | US | disclosed |
| US-20090105305-A1 | Therapeutic Agents - 550 | ASTRAZENECA AB (SE) | 2009-04-23 | — | — | US | disclosed |
| WO-2008075070-A1 | SULFONAMIDE DERIVATIVES FOR THERAPEUTIC USE AS FATTY ACID SYNTHASE INHIBITORS | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | WO | disclosed |
| US-20060211740-A1 | Novel compounds | GLAXO GROUP LIMITED | 2006-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105305-A1 | Therapeutic Agents - 550 | FABP4, GPR119, FASN | KDM4E 2575/4885SMN1; SMN2 2999/4885HSD17B10 59/4885 |
| US-20060211740-A1 | Novel compounds | BACE2, BACE1, PSEN2 | KDM4E 1890/4885SMN1; SMN2 756/4885HSD17B10 2479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.